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Abstract
Chronic non-bacterial osteomyelitis (CNO) belongs to the growing spectrum of autoinflammatory diseases and primarily
affects the skeletal system. Peak onset ranges between 7 and 12 years of age. The clinical spectrum of CNO
covers sometimes asymptomatic inflammation of single bones at the one end and chronically active or recurrent multifocal
osteitis at the other.
Despite the intense scientific efforts, the exact molecular mechanisms of CNO remain unknown. Recent data suggest CNO
as a genetically complex disorder with dysregulated TLR4/MAPK/inflammasome signaling cascades resulting in
an imbalance between pro- and anti-inflammatory cytokine expression, leading to osteoclast activation and
osteolytic lesions.
In this manuscript, the current understanding of molecular patho-mechanisms in CNO will be discussed.
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Introduction
Chronic non-bacterial osteomyelitis (CNO) is an autoin-
flammatory bone disorder. It primarily affects children and
adolescents with a peak onset between 7 and 12 years. How-
ever, CNO can generally occur in all age groups. The clinical
spectrum is variable and ranges from single asymptomatic
bone lesions up to the most severe form of chronic recur-
rent multifocal osteomyelitis (CRMO) [1–7]. Due to this
variable clinical presentation with sometimes rather mild
and unspecific clinical symptoms, diagnosis is frequently de-
layed or even missed. This is particularly worrying, since un-
treated CNO may result in bone sclerosis, pathological
fractures (mainly of the vertebral bodies) sometimes with
subsequent neurological symptoms, growth anomalies, pain
amplification, and psychosocial problems [8–11].
Recent discoveries contributed to a better understanding
of underlying molecular mechanism leading to systemic
inflammation in CNO. However, the exact molecular
pathophysiology remains incompletely understood [9].
Cytokine dysregulation in CNO/CRMO
To our current understanding, several molecular distur-
bances contribute to the molecular pathophysiology of
CNO. Bone inflammation may be the result of dysba-
lanced cytokine expression from innate immune cells
and subsequent osteoclast differentiation and activation,
resulting in bone remodeling and inflammatory bone
loss [4–6, 9, 12, 13].
Dysbalanced cytokine expression
At the time of diagnosis, treatment naïve patients with
CRMO (the most severe form of CNO) exhibit increased
serum levels of pro-inflammatory cytokines IL-6 and
TNF-α, while the immune-regulatory cytokine IL-10 was
not detectable [14, 15]. This observation, together with
the assumption that CNO/CRMO may be an autoin-
flammatory disorder, led to scientific efforts targeting
cytokine expression from innate immune cells, namely
monocytes. In response to stimulation of Toll-like recep-
tor 4 (TLR4) with lipopolysaccharide (LPS), monocytes
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from CRMO patients failed to produce IL-10, while ex-
pressing increased amounts of IL-6 and TNF-α [15].
Interleukin-10 is eponymous to the IL-10 cytokine family,
which (among others) includes the homologues IL-19
(also immune-regulatory) and IL-20 (pro-inflammatory)
[16, 17]. Together with IL10, the IL19 and IL20 genes are
organized in the same so-called IL10 cytokine cluster on
chromosome 1q32. In monocytes from CRMO patients,
expression of IL-19 is decreased when compared to con-
trols, while expression of the pro-inflammatory cytokine
IL-20 is enhanced in response to stimulation with LPS
(Fig. 1) [15, 18].
Impaired IL-10 expression in monocytes from CRMO
patients is (at least partially) caused by reduced activation
of mitogen-activated protein kinases (MAPK) extracellular
signal-regulated kinase (ERK)1 and ERK2 (Fig. 1) [18]. At-
tenuated ERK activation resulted in impaired phosphoryl-
ation and nuclear shuttling of the transcription factor
signaling protein (Sp)-1, subsequently leading to reduced
recruitment of Sp-1 to regulatory elements at the IL10
a
b
Fig. 1 Molecular pathophysiology of CRMO. a The sensing of danger- and pathogen-associated molecular patterns (DAMPS and PAMPS) occurs by pattern
recognition receptors (PRRs), such as membrane-associated Toll-like receptors (TLRs) and cytoplasmic-localized NOD-like receptors (NLRs). TLR4 activation by
lipopolysaccharide (LPS) results in the activation of mitogen-activated protein kinases (MAPK), including extracellular signal-regulated kinases 1 and 2 (ERK1/
2), p38, and Jun kinase (JNK). In response to the recognition of danger signals, multiprotein complexes, so-called inflammasomes, are activated. The NLRP3
inflammasome comprises NLRP3, ASC, and procaspase-1. Inflammasomes mediate caspase-1 activation, which results in cleavage of pro-IL-1β into its active
from IL-1β. In monocytes from CRMO patients, impaired ERK1/2 signaling results in failure to express IL-10 and IL-19. Reduced expression of IL-10 and IL-19
contributes to inflammasome activation and IL-1β release. Pro-inflammatory cytokines IL-1β, IL-6, IL-20, and TNFα increase the interaction of RANK receptors
on osteoclast precursor cells with their soluble ligand RANKL, inducing osteoclast activation and differentiation. b IL10 promoter polymorphisms rs1800896
(-1082A>G), rs1800871 (-819T>C), and rs1800872 (-592A>C) form distinct haplotypes (GCC, ACC, and ATA) that determine transcription factor recruitment.
(MAPK mitogen-activated protein kinase; CRMO chronic recurrent multifocal osteomyelitis; ERK1/2 extracellular signal-regulated kinases 1 and 2; TLR Toll-like
receptor; IL interleukin; JNK Jun kinase; TNF tumor necrosis factor; NF-κB nuclear factor-κB; Casp1 caspase-1; PAMP pathogen-associated molecular pattern;
DAMP danger-associated molecular pattern; RANK receptor activator of nuclear factor-κB; RANKL RANK ligand)
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and IL19 promoters. Expression of pro-inflammatory cy-
tokines, including IL-6 and TNFα, though also depending
on MAPK activation, is increased in monocytes from
CRMO patients. This, however, may be due to unaffected
activation of alternative MAPK pathways, such as p38
MAPK (Fig. 1) [12, 15, 18].
Post-translational modifications to the amino-terminus of
histone proteins and the addition of methyl groups to the
5′-carbon end of cytidine residues in cytidine-phosphate-
guanosine sequences of the genomic DNA (DNA methyla-
tion) represent the two main mechanisms during chromatin
remodeling [19–21]. MAP kinases, including ERK1 and
ERK2, are responsible for the phosphorylation of histone
protein amino termini. Impaired activation of ERK leads to
reduced histone 3 serine 10 (H3S10) phosphorylation at the
IL10 and IL19 promoters in monocytes from patients with
CRMO (Fig. 1) [15, 18]. Histone H3S10 phosphorylation is
an activating epigenetic modification, resulting in an “open-
ing” of regulatory regions to transcription factor binding and
RNA polymerase recruitment [19, 20]. Therefore, reduced
H3S10 phosphorylation further contributes to reduced Sp-1
recruitment. Also, DNA methylation is altered in monocytes
from CRMO patients. DNA methylation patterns in CRMO
are complex and incompletely understood. Increased DNA
methylation (an inactivating epigenetic modification) of IL19
contributes to impaired IL-19 expression, while methylation
of the proximal IL20 promoter was reduced, contributing to
increased IL-20 expression [6, 9, 12, 15, 18, 22].
Osteoclast activation and differentiation
We demonstrated that monocytes from CRMO patients
express increased levels of pro-inflammatory cytokines
(IL-6, TNF-α, IL-20), while they fail to produce immune-
regulatory cytokines IL-10 and IL-19 [18, 22].
The question of how imbalanced cytokine expression
may translate into the bone inflammation and the expres-
sion of CRMO remained unanswered. Recently, NLRP3
inflammasome activation was linked to inflammatory
bone loss and synovial inflammation in IL-10-deficient
mice [23]. Two studies demonstrated increased NLRP3
and IL-1 mRNA expression in peripheral blood mono-
nuclear cells (PBMCS) [24] and monocytes [22] of CRMO
patients. We linked impaired IL-10 and IL-19 expression
with subsequently increased IL-1β mRNA expression and
IL-1β proteins in monocytes from CRMO patients [22].
Indeed, enhanced inflammasome activation and IL-1β se-
cretion from monocytes was reversed by co-culture with
recombinant IL-10 or IL-19 [22].
Taken together, observations in IL-10-deficient animals
and CRMO patients support the hypothesis that imbal-
anced expression of anti-inflammatory (IL-10, IL-19)
and pro-inflammatory (IL-1β, IL-6, TNFα, IL-20) cyto-
kines result in bone inflammation [6, 22]. Data from
metabolic studies indicate that imbalanced expression of
anti- and pro-inflammatory cytokines contribute to en-
hanced interactions between the receptor activator of
nuclear factor-κB (RANK) surface receptor and its sol-
uble ligand RANKL on osteoclast precursor cells (Fig. 1)
[13, 25, 26]. Interactions between RANK and RANKL
result in osteoclast differentiation and activation and
may therefore contribute to inflammatory bone loss in
CNO. However, the involvement of these molecular
events in CNO remains to be scientifically proven.
CNO as a genetically complex disorder
Genetic predisposition for CNO/CRMO has been sus-
pected by the occurrence of familial monogenic disorders
including non-infectious osteomyelitis as one of the main
clinical features. Patients with Majeed syndrome (caused
by homozygous mutations in the LPIN2 gene) [27], the
deficiency of interleukin-1 receptor antagonist (DIRA;
caused by autosomal recessive loss-of-function mutations
in IL1RN) [28–30], and pyogenic arthritis, pyoderma
gangrenosum and acne syndrome (PAPA; caused by auto-
somal dominant loss-of-function mutations in PSTPIP1)
[31] develop severe aseptic osteomyelitis. Because of the
central involvement of increased IL-1 signaling and
inflammasome activation in these monogenic disorders
involving CNO as a key symptom, inflammasome activa-
tion and IL-1 release appeared likely involved in the
pathophysiology of “sporadic” CNO. However, screening
of IL1RN did not deliver disease-causing mutations in a
cohort of CNO patients [32].
Associations of CNO/CRMO with other autoinflamma-
tory disorders, such as psoriasis or inflammatory bowel
disease, and the occurrence of familial clusters further
suggest a common genetic predisposition for sporadic
CNO [1, 7, 33, 34]. Golla et al. performed an association
study in CNO patients identifying a potential susceptibility
locus on chromosome 18q21.3-22 [35]. However, findings
of this study were not confirmed in subsequent efforts in
larger and independent cohorts. Recently, we analyzed the
polymorphisms in the proximal promoter region of the
immune-regulatory cytokine interleukin 10 (IL10) in a co-
hort of CRMO patients. Three IL10 promoter polymor-
phisms rs1800896 (c.-1082A>G), rs1800871 (c.-819T>C),
and rs1800872 (c.-592A>C) form distinct haplotype blocks
(GCC, ACC, and ATA) that influence transcription factor
recruitment capacities to regulatory elements within the
proximal promoter [16, 17]. Based on promoter haplo-
types, IL-10 expression can be stratified from “high”
(GCC), over “medium” (ACC), to “low” (ATA). Previously,
recruitment of Sp-1 was shown to depend on “permissive”
GCC IL10 promoter haplotypes, which may contribute to
disease outcomes in infectious disorders [15, 17, 36]. Un-
expectedly, we determined an enrichment of IL10 pro-
moter haplotypes encoding for “high” IL-10 expression
(GCC), while we did not find a single CNO patient with
Hofmann et al. Molecular and Cellular Pediatrics  (2017) 4:7 Page 3 of 6
homozygous ATA haplotypes in our cohort. Thus, IL10
polymorphisms can by themselves certainly not explain
impaired IL-10 secretion by monocytes from CRMO pa-
tients [15, 17]. Therefore, it appeared likely that additional
molecular mechanisms contribute to altered IL-10 activation
and secretion in CNO (see above). Indeed, the absence of
IL10 promoter haplotypes encoding for “low” IL-10 expres-
sion suggests that individuals with the aforementioned mo-
lecular defects contributing to reduced IL-10 expression in
CNO/CRMO and ATA haplotypes may develop more se-
vere symptoms and will therefore not be diagnosed with
CNO but potentially some other inflammatory condition.
While this hypothesis sounds promising, it currently re-
mains to be investigated and proven in larger multi-national
cohorts.
Recently Cox et al. identified mutations in FBLIM1 in
two CNO patients from South Asia using whole-exome
sequencing [37]. While the exact function of Filamin
Binding LIM Protein 1 (FBLIM1) remains somewhat un-
clear, it acts as an anti-inflammatory molecule by regu-
lating receptor activator of NF-κB ligand (RANKL)
activation [38]. Interactions between RANK receptors
on the surface of osteoclast precursor cells and soluble
RANKL result in osteoclast generation and activation,
thereby contributing to bone remodeling and inflamma-
tory bone loss [13, 25, 26]. Expression of FBLIM1 is reg-
ulated by STAT3 [37]. Since IL-10 induces the activation
of STAT3, reduced IL-10 expression may result in im-
paired STAT3 activation and subsequently altered
FBLIM1 expression. Indeed, both reported patients carry
IL10 promoter haplotypes encoding for “low” IL-10 ex-
pression. Therefore, the combination of IL10 promoter
haplotypes encoding for “low” gene expression together
with FBLIM1 variants may result in CNO [16, 39].
Therapeutic implications
Treatment of CNO is based on personal experience, expert
opinion, case reports, and small case series. Nonsteroidal
anti-inflammatory drugs (NSAIDs) are generally used as
first-line therapy [11, 14, 40–45]. Anti-inflammatory effects
of NSAIDs are achieved through inhibition of cyclooxygen-
ase enzymes. Recently, NSAIDs were demonstrated to exert
variable suppressive effects on inflammasomes [46]. Efficacy
of NSAIDs in CNO may therefore be explained by the in-
volvement of pro-inflammatory monocytes in the patho-
physiology of CNO that likely contribute to the generation
and activation of osteoclasts. Prostaglandins are involved in
osteoclast activation, and the inflammasome activation is a
hallmark of pro-inflammatory monocytes in CNO [6]. As
NSAIDs, corticosteroids suppress prostaglandin production,
which is achieved through the inhibition of phospholipase
A1. Furthermore, corticosteroids reduce the expression of
NFκB-mediated pro-inflammatory cytokines, including IL-1,
IL-6, and TNF-α [6]. Some authors report successful short-
term use of corticosteroids in CNO, usually over a few
weeks [6, 40].
Tumor necrosis factor α centrally contributes to bone
inflammation in CNO. Thus, blockade of TNF-α appears
a promising therapeutic intervention. Indeed, several
small case series report induction of clinical and radio-
logical remission in CNO in response to TNF blockade
[6, 8, 11, 40, 47, 48].
The bisphosphonate pamidronate inhibits osteoclast
activity and exerts incompletely understood effects on
inflammatory cytokine expression [6]. Pamidronate was
reported to induce rapid and long-lasting remission in
most CNO patients [6, 8, 49–52].
Provided the previously described overactivation of
inflammasomes and increased IL-1 release from PBMCs
and monocytes from CNO patients, surprisingly, few
cases of anti-IL-1 treatment have been reported with
mixed response and variable outcomes (Girschick H.J. et
al., unpublished data). The potential explanation for the
poor response may include low tissue concentrations
and pathophysiological heterogeneity in CNO among
others.
Conclusions
Dysregulated cytokine expression from monocytes cen-
trally contributes to the inflammatory phenotype of CNO.
Recent reports on genetic and molecular alterations in
CNO patients indicate complex and variable immune
pathology. Response to previously empiric treatment can
now be explained, based on molecular patterns in immune
cells from CNO patients.
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